Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 1.37M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -109k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -28.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
| Dividend | N/A | Price/Book | 1.43 | EPS next 5Y | - | 52W High Chg | -67.00% |
| Recommedations | - | Quick Ratio | 8.07 | Shares Outstanding | 136.98M | 52W Low Chg | 138.00% |
| Insider Own | 8.17% | ROA | -6.87% | Shares Float | 125.69M | Beta | -3.63 |
| Inst Own | 0.02% | ROE | -13.02% | Shares Shorted/Prior | -/- | Price | 0.01 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 14,041 | Target Price | - |
| Oper. Margin | - | Earnings Date | Aug 28 | Volume | 4,201 | Change | 0.00% |
About VAXIL BIO LTD (CA)
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.
VAXIL BIO LTD (CA) News